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The present investigation was undertaken to obtain conclusive data on the 
development and status of antibodies in human beings during the  course of 
infection with the virus of poliomyelitis. Previous studies on this problem have 
been extensively reviewed by Paul and Trask (1, 2), Harmon and Harkins (3), 
Brodie, Fischer, and Stillerman (4), Burnet and Jackson (5), Kessel, Stimpert, 
and Fisk (6), Aycock (7), Turner and Young (8), and Sabin (9). The main issues 
and controversial findings will be summarizedi however, to indicate how they 
determined the design of the present study. 
Tests with  strains  of poliomyelitis virus  which had undergone many passages in monkeys 
("MV," "A ycock," or others) (1-7)  or in mice (Lansing)  (8, 10-15) invariably  gave a similar 
pattern, which varied only quantitatively  in different investigations. The sera obtained during 
the acute stage of the disease either had no antibody and, with certain exceptions, developed 
none during convalescence,  or else neutralized the virus and, when tested quantitatively, only 
rarely increased in titer during convalescence. 
Tests with strains of poliomyditis  virus of recent human origin (1, 2, 4-7, 16, 17) especially 
when the virus and the patients were derived from the same outbreak, yielded different results 
in different investigations. Thus,  Paul and Trask (1), Howitt  (16), Kessel, Stimpert,  and 
Fisk (6), and Aycock (7) reported that a considerable number of patients' convalescent sera 
which failed to neutralize standard,  laboratory,  multiple-passage virus possessed antibodies 
for a strain of virus recovered during the same outbreak from which the patients were derived. 
Using these freshly isolated strains,  it was occasionally possible to demonstrate absence of 
antibody in the serum obtained during the acute phase of the illness and presence during 
convalescence,  when similar tests with the multiple-passage, laboratory strains either revealed 
no difference  or yielded negative results. On the other hand, Brodie, Fischer, and StiUerman  (4) 
and Burnet and Jackson (5) found no difference in the results of the neutralization tests with 
"standard" laboratory  strains as compared with virus recovered during the same outbreak 
from which their patients were derived. The difficulties in appraising these data, which were 
appreciated by many of the investigators, stemmed from one or more of the following  circum- 
stances: 
(a) the tests carried out in monkeys were usually done with single  animals or small numbers 
of animals, and one could not be certain of occasional differences between acute and con- 
valescent sera; (b) the viruses of recent human origin might have been of either low or high 
potency and virulence, and since the tests were carried out with unknown quantities of virus 
(in terms of paralytic or infective doses), the comparative studies were consequently neither 
* Aided by a grant from The National Foundation for Infantile Paralysis, Inc. 
Senior Fellow in Pediatrics, National Research Council. 
349 350  ANTIBODY RESPONSE OF PATIENTS WITH  POLIOMYELITIS 
definitive nor conclusive; (c) the accumulating evidence that different strains of poliomyelitis 
virus of recent human origin differed in antigenic constitution, and the lack of certainty that 
any one epidemic was caused by a single strain of virus, were regarded by many as the most 
probable explanation for the discrepant and often incomprehensible  results. 
Since the extent of antigenic variation among different strains of poliomyelitis virus was 
still unknown,  it was apparent to a number of investigators that the antibody response in 
human poliomyelitis  had to be elucidated first of all, by using virus recovered from the indivi- 
dual patient under investigation. At the time the present study was planned this had been 
done in only two instances. Trask and Paul (2) recovered virus from the throat of a child with 
a minor illness (abortive poliomyelitis) and showed that while the serum obtained during the 
1 day of illness failed to protect a monkey, the serum obtained 25 days later tested in another 
monkey prolonged the incubation period su~ciently to suggest partial protection. Sabin and 
Ward (18) recovered a virus from the stools of a laboratory worker, who acquired  paralytic 
poliomyelitis, and showed that it was immunologically identical with a strain of virus of recent 
human origin ("Per.") to which she was exposed and different from the "M.V."  virus; this 
patient's acute phase serum  failed to neutralize both the "M.V."  and the "Per." viruses, 
while the 1 month, 2 month, and 10 month convalescent  sera neutralized the "Per." virus 
(tested in 5 monkeys) but not the "M.V."  virus (tested in 3 monkeys). It should be stated, 
however,  that the potency of the "Per." virus used in this test was not established  and it 
might have been in the minimal infective range. 
The  review of previous work made it abundantly clear,  that any definitive 
study of the antibody response in human poliomyelitis would require not only 
the use of strains of virus recovered from the individual patient, but also, with 
less regard for the  cost of large numbers  of monkeys than  was  necessary in 
earlier years, the same  quantitative  techniques  which  are  commonly utilized 
in the study of other virus infections. 
Plan of Study and Methods 
The  goal was  to  collect approximately 20  patients  with paralytic or non- 
paralytic poliomyelitis from whose alimentary tract virus  would be recovered 
during the first days of the illness and from whom serum specimens would be 
available within 4  days after appearance of the first symptom, however slight, 
and at 2, 4, and 12 weeks after onset. The monkeys to be used for recovery of 
the virus from any one patient would be kept isolated to prevent them from 
picking up  virus from  the  stools of  monkeys  inoculated with  material from 
other patients. Material from the first monkeys to succumb with poliomyelitis 
was  to  be  passaged  to  another  group  of  monkeys  (at  least  2)  and  if  these 
developed poliomyelitis, their spinal cords and medullae were  to be used for 
the preparation of a  centrifuged 20 per cent suspension in saline. This second 
generation  virus material was  to  be  stored frozen  in  a  box  containing  solid 
CO~ and used for preliminary titration of the potency of the virus. Any strain 
with a  50 per cent poliomyelitis dose  (PDso)  of approximately 10  -3 or more, 
would be considered suitable for the projected quantitative neutralization tests 
with  the  patient's  sera.  Since  one  could  not  predict  the  behavior  of  these 
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retitered each time a neutralization test was carried out and sera to be compared 
were to be tested simultaneously. All sera were to be stored in a dry ice refrigera- 
tor. In order to evaluate the specificity of the antibody response to the patient's 
own virus,  the same sera were also to be tested in mice against the Lansing 
strain of poliomyelitis virus. This plan was strictly carried out and extended 
when the unexpected results of the study required further elucidation. 
Sdection  of Patients.--In order  to  achieve the goal just described it was expected  that 
approximately twice the number of patients ultimately desired would have to  be studied. 
Accordingly, material was finally collected from 40 patients during the course of moderate 
outbreaks of poliomyelitis in Cincinnati, Ohio, Akron, Ohio, and Boise, Idaho and vicinity 
in 1947.  Each of these patients was examined by either one of us before selection and sub- 
sequently until the clinical diagnosis of poliomyelitis and ultimate paralytic or non-paralytic 
nature of the disease were established.  1 Pleocytosis, with a  minimum of 20 leukocytes per 
c. ram. of cerebrospinal fluid, along with nuchal-spinal rigidity and the other clinical manifesta- 
tions usually seen in the non-paralytic and paralytic forms of the disease were present in all 
the selected patients. The time of onset was calculated from the appearance of the first relevant 
symptom, and the study was limited to patients admitted to the hospital within a few days 
after onset. 
Recovery of Virus from the Alimentary  Tract.--Material  from the oropharynx on 2 cotton- 
tipped applicators, and stools or saline enema returns were obtained daily for a period of 3 days. 
Each pair of cotton swabs was placed in a  screw-capped lusteroid tube containing 1 ml. of 
sterile, distilled water and stored frozen in a box with solid CO,. The stools or enema returns 
were similarly stored in the frozen state in waxboard cartons. The liquid expressed from the 
thawed cotton swabs was centrifuged at 4,000 R.P.~.  on an angle centrifuge for 30 minutes, 
treated with anesthetic ether, recentrigued at the same speed and time, and the supernatant 
liquid, after being shown to be free of bacteria by culture on blood agar, was used for intra- 
cerebral inoculation into each of 2 monkeys. The same 2 monkeys received the same patient's 
untreated stool suspension intranasally once a  day for 4  to  10 days,  and the ether-treated, 
centrifuged extract of the stools intraabdominaliy in amounts of 20 ml. daily for 1 to 4 days 
(19). Monkeys which developed paralysis were sacrificed within less than 24 hours to obtain 
material for passage at the optimum time and for histologic confirmation of the diagnosis. 
Monkeys which failed to develop paralysis were sacrificed 30 to 35 days after inoculation for 
histologic study to detect the presence of lesions associated with experimental non-paralytic 
poliomyelitis (20). When both monkeys, receiving material from the same patient, developed 
paralysis, their tissues were pooled for passage into 2 additional monkeys. The second genera- 
tion virus was then used for intracerebral titration as shown in the protocols of the appendix. 
Each strain of virus was stored in the frozen state as a 20 per cent centrifuged suspension in 
saline, which was regarded as the 1:5 dilution. Further dilutions for titration and neutraliza- 
tion tests were prepared in saline. 
Neutralization Tests in Monkeys.--Virus dilutions of 1:5, 1:50, 1:500, etc. were mixed with 
equal amounts of saline for control or with the undiluted sera to be tested, to yield final dilu- 
tions of virus of 10  -1, 10  m, 10  --a, etc. The mixtures were left at room temperature (20 to 25  ° C.) 
for 1 hour, in a refrigerator at approximately 4 to 6 ° C. overnight for about 15 hours, and were 
1 We are indebted to the staffs of The Children's Hospital, Akron, Ohio, and the St. Luke's 
Hospital,  Boise,  Idaho,  for permission to study their patients.  Special thanks are due Dr. 
Margaret Baker in Akron and Mr. A. W. Klotz in Boise, for the collection and forwarding of 
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kept in an ice bath during the course of the inoculations. Each of 3 rhesus monkeys received 
0.5 ml. of each mixture intracerebrally, the inoculation being carried out with a  1 inch long 
needle deep into the frontal lobes of one side. Monkeys which failed to develop typical paralysis 
were sacrificed  28  to 35  days after inoculation, and if histological changes compatible with 
non-paralytic poliomyelitis were found, they were so recorded and counted in the calculation 
of the PDs0 of the virus. As might have been expected the PD~0 titer of aliquots of the same 
virus preparation varied in  different fitrations within approximately one tenfold dilution 
without reference to the time of storage in the frozen state. For this reason the neutralization 
indexes (ratio of titer of virus in saline and titer of virus in mixture with test serum) were 
calculated both from the control titer of the virus in the simultaneous test and from the 
cumulative titer obtained in 3 separate titrations. The neutralization index calculated from 
the cumulative control titer is used in the summaries, because it is believed to be closer to the 
actual value. 
When it proved necessary to carry out tests in which the virus dose was constant and the 
dilution of serum was varied, an attempt was made to use 50 PD~0, based on two preceding 
titrations of the virus preparation, although the final data for this calculation were occasionally 
not available because the histologic studies had not been completed. However, the dose so 
selected, turned out to vary from 13 to 1,000 PDs0, as calculated from a third, simultaneous 
titration of the virus, and from 32 to 200 PD~0 as calculated from the cumulative control titer 
derived from the 3 titrations. The selected dose of virus (in twice the concentration to allow for 
dilution upon addition of an equal amount of saline or indicated dilutions of serum) was mixed 
with saline or the fourfold dilutions of serum, incubated in the same manner, and 0.5 ml. of 
each mixture was injected intracerebrally into each of 4 monkeys. The 50 per cent protective 
serum dilution end-point was calculated by the method of Reed and Muench (21). 
Neutralization Tests with Lansing Virus in M/ce.--This strain of virus was obtained in its 
198th mouse passage from Dr. H. A. Howe. The virus used in these tests consisted of a large 
pool of centrifuged 10 per cent suspension in saline (regarded as the 1:10 dilution) prepared 
from the spinal cord and brain stems of several hundred mice. It was stored in 1 ml. amounts 
in sealed glass ampoules, frozen with solid CO2. Titrations using 8 mice per dilution (prepared 
in saline) were carried out each time a test was done. The cumulative LDs0 of one lot of virus 
based on 23 individual titrations over a period of 6 weeks was 10  -a~ with a range of I0  -~.s to 
10  -4~ and 74 per cent of the titers in the range of 10  -3'3 to lff-8.L In the neutralization tests 
the 1 : 10 and 1:50 dilutions of virus were mixed with equal parts of the undiluted sera, yielding 
final dilutions of virus of 1 : 20 and 1 : 100, and after 1 hour at room temperature, 8 mice were 
inoculated intracerebrally with 0.03 ml. of each mixture. The LD~0 titers of the virus in the 
presence of a given serum were estimated from the number of mice which died between 2 and 
28  days after inoculation. The  neutralization indexes were estimated by  comparing these 
LD60 titers with the cumulative LDs0 titer of the lot of virus used in the test. Under the 
conditions of the test a neutralization index under 30 was regarded as negative (0),  between 
30 and 50 as questionable (4-), between 50 and 100 as positive (-[-), and over 100 as positive 
(-4--4-). When it was necessary to test various dilutions of some of the positive sera against a 
constant amount of virus, fourfold dilutions of the sera were mixed with equal amounts of 
virus diluted to contain 100 LDs0 per 0.03 ml., so that the final dose of virus used was 50 LDs0. 
The 50 per cent protective serum dilution end-point was then estimated by the method of 
Reed and Muench (21). The acute phase sera from each of the 40 patients were tested first. 
Those which yielded negative or questionable results were then retested simultaneously with 
the 3 month convalescent serum from the same patient. 
RESULTS 
Recovery of  Virus from  the Alimentary  Tract and  Status  of Antibodies for 
Lansing Virus in Individual Patlents.--Twenty strains of virus were recovered Recovery of Virus and Status o 
Type of  City 
illness 
Paralytic 
Patient 
Name  Age 
yrs. 
i 1  Fro  0.~ 
2  Ric  0.5 
3  Ris  1.5 
Cincinnati  4  Hopk  2 
1947  5  Fin  8 
6  Hopp  1.~ 
7  Wol  2 
8  Bre  12 
9  Ten J  7 
Akron  10  Obe  13 
1~7  11  Kau  11 
L2  Smi  13 
I  13  Gaf  12 
i 
Non.paralytic 
i 
TABLE  I 
r  Antibodies for Lansing Virus in Individual Patients 
m~ 
oo 
N 
days 
3 
5 
3 
2 
0.5 
4 
3 
5 
2 
1 
3 
3 
4 
i  Hof  4  3 
2  Vau  8  5 
i 
3  Cah  3  2 
Cincinnati  4  Red  7  4 
1947  5  Sea  7  1 
6  Gil  11  2 
7  Hal  12  3 
8  Bra  15  1 
9  Wal  i3  2 
l0  Pet  13  2 
11  Fal  36  3 
12  Kni  2  1 
13Yea  ]22  0.3 
14  Col  1  1 
15  Sic  15  l 
Akron  16  Cur  3  4 
1947  17  Let  [ 5  1 
18  Sny  5  I 
19  Wor  7  1 
20  Hud  II  3 
21  Ten S  112  4 
22  Fru  12  4 
23  Gra  16  4 
24  Den  5  0.3 
Boise,  25  Mac  5  3 
Idaho 
1947  26  Ack  18  1 
27  Kra  $6  3 
Virus 
recovery 
~  Titer  Convales- 
in  Acute 
mon-  phase  cent 3 
--  keys$  mos, 
10- 
+  3.3  ++ 
+  3.6  --;--  ++;++ 
+  3,8  "4-; --  -- 
+  4.0  ++ 
+  2.9  --; --  -- 
+  1,o+?  -;-  - 
-  ++ 
÷  4.1  -t-;  --;  -  +;+  50--;  25--;  25 
+  3.6  --; --  --  I0--;  S-- 
+  <1.0  ++  320+ 
÷  <1.o  ±;  -  -  5o-;  lO- 
--  ++  320+ 
+I~  4.3  --; --  --  20--;  6-- 
+l  2.3  --;--  +;++  15--;6-- 
-  --;  --  --  20-;  16-- 
--  -;  --  -  i0-;  5- 
_~+  --  20--;5-- 
-  200+ 
-  ++  250+ 
-  ++  2so+ 
..~  4.2  --;--  --  20--;5-- 
2.5  +; ++  +  80+; 140+ 
+  2.3  --;--  --  13--;6-- 
'+ <2.0  :t:; -  -  50-;  10- 
+  <2.0  -b;  --;  --  -4-:; -4-  50--; 8--; 6 
I+  t.o+?  ++  250+ 
+  <1 .o  +;  +  ++  lOO; 8o 
--  --;  -  10-;4- 
-  -  20-;  6- 
--  --;  --  --  20--;  10-- 
--  +;  --  --  63--;  13-- 
-  ++  200+ 
--  --  ;  --  ++  20-- ; 13-- 
-  ++  250+ 
--  --  13--;  6-- 
+  1.o  ++ 
--  -;  --  :h;  +  20--;  6-- 
-  ++  25o+ 
-  ++  320+ 
"Lansing" antibody in serum 
Estimated N.I.* 
Acute phase  Convales- 
cent 3 mos, 
200+ 
lO-;S-§  14o+;  16o+ 
32-- ; 13--  4-- 
320+ 
15--; 13--  6-- 
20--; 5--  5-- 
320+ 
20--; 15--  10-- 
63+; 80+ 
$-- 
16-- 
5-- 
50+; 100+ 
6-- 
13-- 
4-- 
4-- 
80+ 
10-- 
20-- 
40+;  32 
14o+ 
20--;  16 
4-- 
5-- 
20-- 
125+ 
5-- 
125+ 
40+; 63+ 
* N. I. =  neutralization  index. 
$ This refers to the cumulative PD60 based on 3 intracerebral  titrations  in monkeys of a  single lot of virus 
consisting of second generation monkey material, except in paralytic patient 5, where third generation virus was 
titrated. 
§ Two or more values separated by a semicolon indicate the results of repeated tests; the minus sign after a 
neutralization index indicates that the estimated value might be less than the actual  value, while the plus sign 
indicates that it might be greater. 
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from the 40 patients under investigation--10 strains from the 13 patients who 
ultimately developed the paralytic form of the disease, and 10 from the 27 pa- 
tients with a non-paralytic illness. Using 20 per cent suspensions of the spinal 
TABLE  II 
Antibodies in Undiluted Acute and Convalescent Sera against Virus Recovered from Patient's 
Alimentary Tract during Acute Phase of Illness Contrasted with Those 
against Lansing Strain of Poliomyelitis Virus 
Neutralization index of 
undiluted serum versus 
Ultimate clinical 
course 
Non-paralytic 
Paralytic 
Patient 
Wal 
Hof 
Obe 
Ris 
Fin 
Ric 
Ten.J. 
Hopk 
Fro 
Time 
after onset  Patient's  Lansing 
virus  virus 
(Tests in  (Tests  in 
monkeys)  mice) 
days 
2  16  5-- 
92  1600  4-- 
3  10--  6-- 
91  63  5-- 
1  400+  5-- 
94  800+  5-- 
3  200  13-- 
89  63+  4-- 
0.5  80+  13-- 
93  250+  6-- 
5  8OO+  5- 
91  1250+  140+ 
2  25OO+  25 
91  4000+  80+ 
2  2000+  320+ 
92  3200+ 
3  630+  200+ 
90  400+ 
cords and medullae of the monkeys which succumbed after inoculation with the 
human material., each of these strains produced paralytic poliomyelitis  in the 
intracerebrally inoculated monkeys used for passage. However, when the second 
generation  virus material was  titrated in monkeys, only 9 of the 20  strains 
proved to have titers of approximately 10  -3 or more (Table I). It may be note- ALEX  J.  fiTEIGMAN  AND  ALBERT  B.  SABIN  355 
worthy that of the 10 strains derived from paralytic patients, 7 were of the more 
potent variety, while only 2 of the 10 strains from non-paralytic patients were 
in this category. 
The tests for Lansing antibody in the serum of these 40 patients (Table I) 
indicated that 24 or 60 per cent had no antibody for this strain of poliomyelitis 
virus during the acute phase of the illness. Among the 20 patients from whose 
alimentary tract poliomyelitis virus was recovered in monkeys, 13 or 65 per cent 
had no antibodies for the Lansing virus during the acute phase.  When the 
acute phase sera were retested simultaneously with the 3 month convalescent 
sera of the 24 patients who had no Lansing antibody early after onset of the 
illness, it was found that 5 (21 per cent) had become definitely positive and one 
questionably so. Among the 13 patients from whom virus was recovered and 
whose serum was without Lansing antibody during the  acute phase,  3  and 
possibly 4 developed this antibody during convalescence while 9 did not. Ac- 
cordingly, it appeared possible that the infections we studied might have been 
caused by viruses of different antigenic constitution and that some of them were 
probably related immunologically to the Lansing strain. However, the tests to 
be reported did not support this assumption. 
Tests with Undiluted Acute and Convalescent Sera versus Homologous Strains 
of Virus.--The tests performed with the 9 strains of virus which had an intra- 
cerebral PD60 of approximately 10  -3 or more are summarized in Table II, and 
the individual protocols are presented in the appendix (Tables VIII to XVI). 
The 2 patients with the non-paralytic illness had no significant amounts of anti- 
body for the virus recovered from their own alimentary tract early after onset, 
while the 3 month convalescent sera neutralized the homologous virus but not 
the Lansing virus. In these 2 patients it might be possible to conclude on sero- 
logic grounds that the strains  of virus recovered from them were responsible 
for the infection under investigation. The results obtained with the sera of the 
7 paralytic patients were unexpected, however, in that all the acute phase sera, 
even those obtained 12 to 24 hours after appearance of the first symptom, neu- 
tralized almost completely the  maximum amount of  the  homologous virus. 
The tests on the undiluted, 3 month convalescent sera yielded essentially the 
same results, and it became apparent that the neutralization test, employing 
undiluted sera against varying amounts of the homologous virus,  could not 
indicate the character of the antibody response in these paralytic patients. It 
was of interest to note that 5 of these 7 acute phase sera, which had antibodies 
for the patient's own virus,  failed to neutralize the Lansing virus, and that 
Lansing antibodies became demonstrable in the 3 month convalescent sera of 
2 patients in this group. In former years when such tests were not carried out 
with the patient's own virus, antibody was not infrequently found in sera ob- 
tained during the earliest stages of infection, but it was generally believed that 
such antibody was not against the infecting strain of virus and was probably 356  ANTIBODY RESPONSE OF PATIENTS WITH POLIOMYELITIS 
present  prior  to  the  infection  under  investigation.  Since  the  present  data 
showed that  such findings were even more frequent in  tests with strains  of 
virus recovered from the patient's own alimentary tract, and since there was 
no way of determining whether this antibody was present before the present 
infection it became necessary to determine whether the homologous antibody 
found so early after onset was static or changed during convalescence. Since 
TABLE III 
Demonstration of Increase in Titer of Homologous Antibodies during Conralescence by Tests on 
Varying Dilutions of Serum against Constant Amount of Virus 
Patient 
Obe 
Ris 
Fin 
Ric 
Ten J 
Hopk 
Fro 
50 per cent serum 
dilution  end-point 
Undiluted? 
1:32 
1:3 
1:13 
1:6 
1:97+? 
1:16 
1 : 107+? 
I:1 
1:26 
1:16 
1 : 107+? 
0? 
1:3 
PDs, of virus in test based on 
Simul-  Cumu. 
taneous  lative 
titration  titer 
200  80 
630  125 
160  40 
32  4O 
1000  125 
13  32 
320  200 
the tests on the undiluted sera failed to show a significant, quantitative differ- 
ence between the acute and convalescent sera in the 7 paralytic patients, the 
study was repeated by using various dilutions of sera against a constant amount 
of virus. 
Neutralization  Tests  with  Varying  Dilutions  of  Serum  against  a  Constant 
Amount  of  Virus.--The  results  of  the  tests  (summarized  in  Table  III  and 
shown in detail in the appendix, Tables X  to XVI) on the acute and convales- 
cent sera of the 7 paralytic patients indicate that the antibody for the homo- 
logous virus was in each instance present in lowest titer soon after onset of the ALEX  J.  STEIGMAN  AND  ALBERT  B.  SABIN  357 
illness and in increased concentration 3 months after onset. It can be seen that 
the antibody titers vary considerably in individual patients and that they are 
highest when the dose of virus, calculated from the cumulative titer of the lot 
used, was 32 to 40 PDc0. Smaller amounts of virus were not used in these tests, 
because it was believed that the number of monkeys employed for titration did 
not lend sufficient certainty to  the fate of animals  in  the minimal  infective 
range, and it was desirable that the incidence of poliomyelitis in the absence 
of antibody be as close to 100 per cent as possible. However, it is noteworthy 
that even when 80 to 125 PDs0 of virus were used, increases in antibody titer 
up to 32-fold could be demonstrated in the convalescent sera. The 50 per cent 
TABLE IV 
ntibody  Titers  ~s.  Lansing  and  Patient's  Own  Virus  during  Convalescence in  Individuals 
Possessing  Both at Onset of Illness 
Patient 
Hopk 
Fro 
Time 
after 
onset 
days 
2 
92 
3 
90 
Antibodies for 
Lansing virus 
50 per 
Neutral-  cent 
izatlon  protective 
index of  serum 
]undiluted  dilution 
end-point 
serum  vs. 50 PD~e 
of virus 
320+  1:52 
1:27 
200+  1:20 
1:8 
Antibodies.for patient's 
VIRUS 
Neutral- 
ization 
index of 
undiluted 
serum 
2000+ 
3200+ 
63O+ 
400+ 
50 per cent protective serum 
dilution end-point vs. 
indicated PD~0 of virus. 
1:16  ~.. 
1:107+ ?jOz PD~o 
0?  }200 PD~o 
1:3 
protective serum dilution end-point is undoubtedly affected by the quantity of 
virus  used.  Accordingly  only  sera  tested  simultaneously  against  the  same 
amount of virus can be compared. Although the results in patient Fro.  (ap- 
pendix, Table XVI) were especially irregular, the difference in antibody titer 
between the acute and 3 month convalescent sera in the other patients was from 
4- to 32-fold. It appeared, therefore, that antibody for the homologous virus 
was not static during the course of infection. 
On the other hand, antibody for the Lansing strain of virus failed to appear 
in 5 of these 9 patients, appeared sometime during convalescence in 2, and in 
2 others (Hopk. and Fro.) it was obviously necessary to perform neutralization 
tests with varying dilutions of serum against  a  constant amount of virus in 
order to determine the status of the antibody. The results of this test (Table IV) 
show that in these last 2 patients who,  soon after onset of illness,  possessed 
antibodies for both the Lansing strain and their own virus, there was no increase 
in titer of the Lansing antibody when that for their own virus increased during 358  ANTIBODY  RESPONSE  OF  PATIENTS  WITH  POLIOMYELITIS 
convalescence; the somewhat lower titers of the Lansing antibody in the con- 
valescent sera are probably within the range of experimental error. This specific 
change in antibody titer for the homologous virus in at least 7 of the 9 patients 
studied  suggested that  the  antibody response in human beings may perhaps 
begin very early during the course of infection with poliomyelitis virus. 
Time of Appearance or Increase in  Titer of Antibody against Patient's Own 
Virus and against Lansing Virus.--The data on 4 patients, 2 with and 2 without 
TABLE V 
Time of Appearance and Increase in Titer of Antibodies 
Patient  Group 
Antibody tests negative in acute 
phase 
Antibodypresentinacutephase 
Wal 
Hof 
Obe 
Ten J 
Time 
after 
onset of 
1st 
symptom 
14 
28 
92 
3 
34 
91 
250 
1 
14 
94 
2 
14 
91 
rot Patient's Strain of Virus 
Neutral- 
ization 
index of 
undiluted 
serunl 
16 
1000 
500 
1600 
10- 
6 
63 
4O 
400+ 
800+ 
2500+ 
4O00+ 
50 per cent  protective 
dilution  of  serum rs.  indi- 
cated No. of  PD  of  virus 
Serum  PD6o of 
dilution  virus 
Undiluted? 
1:6  80 
1:32 
1:1 
1:8  125 
1:26 
antibody for their own virus  early after onset,  are  summarized  in  Table V 
(details in Appendix,  Tables VIII, IX, X,  and XI).  In one  (Wal)  of the  2 
non-paralytic patients with little or no antibody soon after onset there was a 
marked  increase  at  14 days, while the other (Hof)  who  showed no  antibody 
at 31 days had a rather poor response at 91 and 250 days. In the case of patient 
"Hof," one  cannot be  certain whether one is dealing with an individual who 
produces antibody poorly or whether the strain of virus which was recovered 
from the alimentary tract was the one actually responsible for the  infection 
under investigation. In the other 2 patients it appeared that the antibody they 
had  soon  after  onset  was  increasing  progressively during  the  course  of  the 
infection but had not yet reached its peak at 14 days, although clinical improve- 
ment had begun at least 1 week before. ALEX  J.  STEIGMAN AND ALBERT  B.  SABIN  359 
TABLE VI 
Time of Appearance of "Lansing" Antibody in Patients Who Developed It during Convalescence 
Type of illness 
Paralytic 
Non-paralytic 
Patient 
Ric 
Ten J 
Ten S 
Vau 
Mac 
Yea 
Time after 
onset 1st 
specimen 
obtained 
-[ 
days 
5 
2 
4 
5 
3 
0.3 
Neutralization  indexes  of undiluted  serum  obtained 
at indicated  intervals  after onset 
1st specimen 
10-; 5-* 
50-; 25--; 25 
20-- ; 13-- 
16-;6-- 
20--; 6-- 
50--;8--;6 
?  3 mos. 
140+ ; 160+ 
63+ ;  80+ 
20-  8-  125+ 
13-1  6-1  50+; 10o+ 
4--[125+ 1  40+;  63+ 
4  / 20  40+ ;  32 
* See Table I for legends. 
TABLE VII 
Immunologic  Relationship  of  Viruses  Recovered from  Patients  Who  Devdoped  "Lansing" 
Antibody during Convalescence 
Strain of virus 
Ten J 
(Tests in monkeys) 
~,.Jc 
(Tests in monkeys) 
Lansing 
(Tests in mice) 
Serum used 
,cidence of poliomyelitis  at indicated 
fi~l dilutions  of virus 
10--2 
None--saline  9/9 
"M.V." antiserum (the-  3/3 
sus) 
"Ten J" patient's con-  0/6 
valescent serum 
None--saline  9/9 
"M.V." antiserum  3/3 
"Ric" patient's convales-  0/5 
cent serum 
None--saline  36/39 
"M.V." antiserum  0/8 
"Ric" patient's convales-  1/8 
cent serum 
"Ten J"  patient's  con-  0/8 
valescent serum 
"Ten  J"  rhesus  conva-  14/I~ 
lescent sera 
"Vau"  rhesus convales-  5/8 
cent serum 
10-____~  ! I0-~ 
8/9  3/8 
0/3  ]0/3 
P 
I 
7/9  t3/8 
24/40_  4/40 
1/8  -- 
m 
10-5  10-s 
4/9  0/3 
0/6 
m 
u 
On the other hand, among the 6  patients, whose 3  month convalescent sera 
neutralized the Lansing virus, while  those obtained soon after onset did not, 
none of the 14 day and only one of the 28 day convalescent sera had significant 360  ANTIBODY RESPONSE OF PATIENTS WITH POLIOMYELITIS 
amounts of antibody (Table VI).  In 2 of these patients ("Ten J" and "Ric") 
the antibody response was so different for the homologous virus, that it seemed 
doubtful that the virus recovered from their own alimentary tract could be im- 
munologically identical with  the  Lansing  strain.  Tests  shown  in  Table VII 
indicate that an "M.V." monkey antiserum which fully neutralized the Lansing 
virus  failed  to  neutralize  the  viruses  derived  from  patients  "Ten J"  and 
"Ric." Furthermore, the convalescent sera of 2 monkeys paralyzed with the 
"Ten J"  virus  and  of one monkey  paralyzed with  "Vau"  virus  obtained 3 
months after inoculation also failed to neutralize the Lansing virus. It would 
appear, therefore, that in most if not all the patients who developed the Lansing 
antibody during convalescence, both the time of appearance of the antibody and 
the nature of the recovered viruses indicate that the illness under investigation 
was not caused by a virus of the Lansing type. It is,  of course, possible  that 
these patients may have had a subsequent inapparent or clinically unrecognized 
infection with a  Lansing  type virus. On the other hand, it may also be that 
some strains of poliomyelitis virus may be only partially related to the Lansing 
type so that at the peak of the homologous antibody response which seems  to 
occur some weeks after onset of the illness,  the serum may also acquire the 
capacity to neutralize the Lansing virus. 
DISCUSSION 
The data presented in this communication permit a better understanding of 
the  immune response of human  beings to infection with poliomyelitis virus. 
It can be concluded first of all, that when tests are performed with virus derived 
from the patient's own alimentary tract, it is possible in each instance to de- 
monstrate that antibody, specific for this strain, either develops or increases in 
titer early during the course of infection. The totally unexpected finding that, 
as early as 12 to 24 hours after appearance of the first symptom of illness, the 
undiluted serum of 7 of the 9 patients was capable of neutralizing the maximum 
amounts of the patient's own virus presented special problems. Thus it became 
clear that it was not possible to evaluate the immune response of human beings 
to poliomyelitis virus merely on the basis of presence, absence, or slight varia- 
tions  in  amounts of antibody demonstrable in undiluted  serum,  but  that  it 
would be necessary to investigate it quantitatively by determining the maximal 
dilution of serum capable of neutralizing a specified number of infective doses 
of  virus.  At  the  conclusion  of  the  present  investigation  Hammon  and 
Roberts  (22)  reported similar  results  in  tests  on  the  acute  phase  sera  of  7 
paralytic patients, all of which neutralized an undetermined number of infec- 
tive doses of the patient's own virus. These investigators also  demonstrated 
an increase of antibody titer in sera of 3 patients obtained 45 to 80 days after 
onset.  The question requiring elucidation was whether the antibody present 
soon after onset was specific and the result of a  rapid response of the patient ALEX  ~'.  STEIGMAN  AND  ALBERT  B.  SABIN  361 
to the strain of virus responsible for the illness under investigation, or whether 
it was present as a  result of a  previous infection with a  partially related or 
even the same strain of poliomyelitis virus. In the present investigation, tests 
for Lansing antibody on the same sera showed no correlation with the results 
obtained in the tests against the patient's own virus. Furthermore, the antibody 
for the homologous strains of virus was present in the lowest titer during the 
acute phase and increased progressively during convalescence, suggesting that 
what was found soon after onset might represent the beginning of the antibody 
response. However, since no sera were available on these patients prior to the 
onset of  the present  illness,  the  evidence  cannot be  conclusive with regard 
to the prior origin of the antibody found early after onset. 
The pattern of beginning antibody development during the acute phase of the 
illness or within 14 days after onset, which this study suggests for human polio- 
myelitis, is different from the  results obtained in  monkeys infected by the 
intracerebral or intranasal routes but remarkably similar to those in monkeys 
infected by the oral route. Sabin and Olitsky (23) found that the sera of con- 
valescent paralyzed monkeys failed to neutralize as little as 20 infective doses 
of virus at 4 to 5 weeks after the attack and that the antibodies did not appear 
until 2 or 3  months after intracerebral or intranasal inoculation of "M.V." 
virus. However, yon Magnus and Melnick (24) showed that after oral or pharyn- 
geal administration of virus 13 of 17 monkeys, regardless of species, developed 
neutralizing antibodies in varying titer by the first day of paralysis. It is per- 
haps also noteworthy that the clinical course of the disease in our patients 
could not be correlated with the rate of development of homologous antibody, 
since improvement and arrest of paralysis occurred early after onset when the 
titer of antibody in the serum is low and some weeks before it apparently reaches 
its peak. It may appear paradoxical that the only 2 patients without significant 
homologous antibody shortly after onset turned out to have a mild non-paralytic 
illness,  while the 7 patients in the present study as well as the 7 reported by 
Hammon and Roberts (22), possessing such antibody, were all paralytic. How- 
ever, while it is not certain that future studies will yield similar results, these 
observations may perhaps suggest that the rate and quantity of antibody pro- 
duction as well as the paralytic or non-paralytic outcome of the infection may 
depend on the extent of viral multiplication. 
One other observation, having a bearing on the significance of the appearance 
during convalescence of antibodies for the Lansing virus, is worthy of special 
comment. Although most investigations for Lansing antibody in acute and 
convalescent sera from patients with poliomyelitis have yielded inconclusive 
data,  there have been some  (12, 13)  which might be interpreted as possibly 
indicating infection with a Lansing type virus. In the present study, among 24 
patients without Lansing antibody during the acute phase, 6 or 25 per cent 
were found to have such antibody 3 months later. It was of interest therefore, 362  ANTIBODY  RESPONSE  Ol  ~  PATIENTS  WITH  POLIO~M~YELITIS 
that unlike the early appearance of the antibody for the patient's own virus, 
that for the Lansing virus, with  one exception, was absent at  1 month after 
onset in those who had it at 3 months. Furthermore, in at least 2 of these, it 
was possible to show that the virus recovered from the patient during the acute 
phase of the clinically recognizable illness was not antigenically of the Lansing 
type. Since the peak homologous antibody response apparently occurs more than 
2 weeks after onset, it appeared possible that the late appearance of Lansing 
antibody could be the response to a common antigen. However, the possibility 
of a subsequent lnapparent or clinically unrecognized infection with a Lansing 
type virus must also be considered. 
S~RY 
Of 20 strains of virus recovered from 40 patients with poliomyelitis only 9 
possessed a titer of 10  -8 or more, permitting significant quantitative neutraliza- 
tion tests in monkeys. Seven of the 9 high titer strains were derived from patients 
whose  illness was  ultimately paralytic,  and  tests  with  their  undiluted  sera 
indicated that the acute phase as well as the 3 month convalescent specimens 
neutralized  maximum  amounts  of  the  patient's  own  virus.  However when 
varying dilutions of the sera were tested against a  single dose of virus, it was 
found that the antibody was present in lowest concentration early after onset 
and progressively increased in titer over a period of weeks during convalescence. 
The 2 remaining high titer strains were recovered from patients with a  non- 
paralytic illness,  and in both of these the acute phase sera were without signi- 
ficant amounts of antibody for their own virus. Antibody was demonstrable at 
14, 28, and 92 days after onset in one of these patients, while the other had none 
at I month and only a minimal amount at 3 and 8 months. 
Tests  with  the  Lansing  virus  on  the  same  sera,  clearly established  the 
specificity of the antibody response to the strain of virus recovered from each 
patient under investigation.  Five of the 9  patients, whose sera were studied 
with both viruses,  had no antibody for the Lansing virus during  the acute 
phase and none 3 months later. Two had antibody during the acute phase but 
serum dilution tests showed no increase in titer in the 3 month convalescent 
specimen. In 2 others, who were without antibody for the Lansing virus during 
the acute phase but had it at 3 months after onset, it was possible to show that 
this antibody appeared later than 1 month after the illness and that the virus 
recovered from these patients during their illness was not antigenically of the 
Lansing type. 
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APPENDIX 
Protocols of Neutralization  Tests  in  Monkeys  with  Each  of the 9  High  Titer 
Strains  of Virus 
TABLE VIII 
Patient "Wah" Non-paralytic:  8-25--47--onset with "fever," fatigue, nuchal "soreness;" 
8-26--103.6°F.,  nuchal-spinal  rigidity,  cerebrospinal  fluid  (CSF)--27  lymphoeytes,  no 
paralysis. Fever and clinical signs abated in succeeding few days. 
Virus used in all tests: Generation II, pool of spinal cord and medulla of 2 rhesus monkeys 
--cumulative PD~o =  10  -*'z. 
Type of test 
and date 
Initial  virus  ti- 
tration 
4-29-48 
Undiluted  sera 
vs.  varying 
doses of virus 
6-3-48 
Undiluted  sera 
vs.  varying 
doses of virus 
8-29-48 
Serum 
or 
saline 
Saline 
Saline 
Serum 
Serum 
Saline 
Serum 
Serum 
Time 
after 
onset 
days 
2 
92 
14 
28 
I  Poliomyelitis  in monkeys  at indicated  [ 
final  dilutions  of virus 
I  '  PDso 
I  10- 
lO-I  10-2  I0-:  10-4  i  i0-~ 
I 
8,10,12  8,8,@  11,13,C] 0,0,04.2 
I 
i 
--  8,8,0  5,10,0  0,0,0,4.0 
7,8,10  7,12,12  8,0,0  7,0,0  --  3.0 
7,0,0  7,0,0  0,0,0  0,0,0  --  1.0 
--  --  6,8,10  8,8,0  9,0,0 4.5+ ? 
8,9,0  0,0,0  0,0,@  0,0,@  --  1.2 
8,8,24  0,0,0  0,0,0  0,0,@  --  1.5 
Neutralization 
index based on 
"liter  Cumu- 
of virus  lative 
in same  virus 
test  titer 
10  16 
1,000  1,600 
2,000+ ~ 1,000 
1,000+2  500 
Legends for Tables VIII to XVI: 
Figures refer to day after inoculation paralysis first noted in individual monkeys. 
0  =  neither clinical nor histological evidence of poliomyelitis. 
Encircled figure, @, indicates day of death of monkey exhibiting neither clinical nor his- 
tological evidence of poliomyelitis. 
NP  =  non-paralytic poliomyelitis based on histological changes in sacrificed monkey. ALEX  J.  STEIGMAN  AND  ALBERT  B.  SABIN  365 
TABLE  IX 
Patient "Hof:" Non-paralytic: 9-2--47---onset with headache, red throat, 105°F., question- 
able nuchal rigidity, CSF--no ceils; 9-4--irritable, muscular pains, nuehal rigidity, 'CSF--r- 
474 leukocytes (90 per cent lymphocytes); 9-5--first specimens collected, fever, nuchal rigid- 
ty, pain subsiding.  Complete recovery without paralysis in succeeding few days. 
Virus used in all tests: Generation II, pool of spinal cord and  medulla of 2  rhesus mon- 
keys-cumulative PDs,  =  10-4L 
Type of test and date 
Initial virus titration 
2-27-48 
Undiluted sera as. 
varying doses of virus 
5-15-48 
Undiluted sera vs. 
varying doses of virus 
5-20-48 
Serum  Time 
or  after 
saline  onset 
days 
Saline  -- 
Saline  -- 
Serum  3 
Serum  91 
Saline  -- 
Serum  34 
Serum  250 
Poliomyelitis in monkeys at indicated 
final dilutions o.~¢  virus 
10-I 
4,5 
8,8,0 
8,8,9 
6,7,7 
7,8,8 
101  10-s 
6,9,11 
6,8,10 
12,13, 0 
6,7,13 
6,10,  NP 
6,7,9 
7,8,0 
9,0,0 
6,6,7 
5,12,12 
20,0,0 
10"*  10-J  10  -I 
7,7,9  5,0,0  -- 
8,0,0  ~,O,C  [0,0,0 
120,0,(  -- 
0,0,0  --  -- 
9,11,0  -- 
0,0,0  -- 
0,0,0  -- 
PDso 
10- 
4.7+? 
3.7 
3.3+? 
2.5 
4.2+? 
3.5 
2.7 
Neutralization 
index based on 
"liter of 'Cumula- 
virus in  tive  viru~ 
same test  titer 
1 
i 
3--  i  10--? 
16  i  63  I 
s+?  6 
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